ArticleFrontiers in pharmacology2026
Post-marketing safety evaluation of mirogabalin using the JADER database.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mirogabalin, a novel third-generation α2-δ calcium channel ligand, is approved for diabetic peripheral neuropathic pain (DPNP). However, its post-marketing safety profile remains insufficiently characterized, particularly regarding novel signals and comparative safety profiles with established therapies. Objectives: This study aimed to identify and characterize adverse event (AE) signals associated with mirogabalin, evaluate demographic differences, and compare signal strength with pregabalin and gabapentin. Methods: We conducted a pharmacovigilance analysis using the Japanese Adverse Drug Event Report (JADER) database (January 2019-June 2025). Disproportionality analysis was performed using the Reporting Odds Ratio (ROR) and Information Component (IC) methods. Subgroup analyses by sex and age, sensitivity analyses restricted to monotherapy reports, and time-to-onset (TTO) analysis using Weibull modeling were conducted. Results: Among 463 healthcare professional-reported AE reports, 33 positive signals were identified. Beyond known AEs (e.g., dizziness, somnolence), six novel potential signals were detected: pleural effusion (n = 6), contusion (n = 4), toxic encephalopathy (n = 4), Cardiac failure congestive (n = 4), deafness (n = 3), and angioedema (n = 3). Head-to-head comparisons revealed that mirogabalin exhibited significantly higher reporting odds ratios (RORs) than pregabalin for pleural effusion (ROR = 2.39, 95%CI: 1.01-5.65), toxic encephalopathy (ROR = 6.37, 95%CI: 1.99-20.36), contusion (ROR = 3.35, 95%CI: 1.14-9.87), and deafness (ROR = 3.67, 95%CI: 1.04-12.91), and significantly higher RORs than gabapentin for cardiac failure congestive (ROR = 6.05, 95%CI: 1.78-20.54). Subgroup analysis revealed sex- and age-related differences: male patients showed higher reporting proportions of muscle weakness, myoclonus, erythema multiforme, urinary retention, and elevated liver enzymes, whereas females exhibited higher proportions of renal impairment and falls; elderly patients (≥65 years) showed higher reporting frequencies of dizziness and rhabdomyolysis, whereas the 18-65 age group showed higher proportions of hepatic and cardiovascular events. Sensitivity analysis partially supported the stability of some signals, with rhabdomyolysis identified exclusively in monotherapy reports. The median TTO was 6 days (IQR: 2-42), indicating an early-clustering pattern (β = 0.55, 95% CI: 0.50-0.60). Sensitivity analysis after excluding outliers yielded a median TTO of 5 days (IQR: 2-28) with β = 0.72 (95% CI: 0.65-0.80). Conclusion: This study extends the understanding of mirogabalin's post-marketing safety profile by identifying six novel signals and revealing distinct safety signal profiles compared with established α2-δ ligands. Demographic-stratified monitoring strategies are warranted to optimize patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.